Massive Demand Drives Avience Biomedicals IPO Subscription to 365 Times on Final Day
Avience Biomedicals, a leading diagnostics solutions provider, has seen extraordinary investor interest following the culmination of its Initial Public Offering (IPO) bidding process. The company's stock attracted overwhelming demand, witnessing a highly successful subscription rate of 365.06 times on June 22nd. This massive response highlights strong market confidence in the medical consumables sector.Subscription Highlights and Grey Market Verdict
The IPO generated immense interest across various investor segments during the three-day bidding window (June 18-22). The company offered a total of 10.44 lakh shares, seeking to mobilize Rs 30.2 crore, with a price band set at Rs 196 to Rs 208 per share.Demand far surpassed the offer size, with investors bidding for a total of 37.06 crore equity shares through 1.92 lakh applications. Non-institutional investors were the primary drivers of this interest, subscribing their allotted quota 597.6 times.
The Qualified Institutional Buyers (QIBs) showed robust support, reserving portions that were subscribed 196.77 times. Retail investors and QIBs' reserved portions secured subscription rates of 401.35 times and 196.77 times respectively. Market observers noted that the unofficial Grey Market reflected this fervor, with IPO shares trading at more than a 33 percent premium.
Financial Commitment and Anchor Investor Interest
Avience Biomedicals successfully mobilized Rs 8.52 crore from four anchor investors in the initial stages of the offering. These committed funds were secured through Meru Investment Fund, Shine Star Build Cap, Fortune Hands Growth Fund Scheme, and Sanshi Funds. All anchor investments were made at the higher end of the price band, i.e., Rs 208 per share.A total of 4.09 lakh shares were allocated to these four anchor investors in anticipation of the full IPO launch. The company is now set to finalise the IPO share allotment by June 23rd. Participants will be able to commence trading in Avience shares from June 25th.
Corporate Strategy and Fund Utilization
The proceeds generated from this IPO are earmarked for critical future growth initiatives. Of the total funds raised, Rs 15.95 crore is designated for establishing a new manufacturing unit. This facility will be located within the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA) in Gautam Buddha Nagar, Uttar Pradesh.A further allocation of Rs 8.25 crore is earmarked to meet working capital requirements. The remaining amount will be utilized for general corporate purposes and operational expansion.
Company Profile and Market Positioning
Avience Biomedicals is a medical consumable company that operates across both B2B and B2C markets. It specializes in manufacturing vitro-diagnostic (IVD) products and various medical devices.The company currently functions as distributors and traders of medical equipment, in addition to its manufacturing activities. Avience serves pathology labs, hospitals, microbiology labs, and research centers. Currently, the company operates from a leasehold manufacturing facility located in Gautam Buddha Nagar, Uttar Pradesh. Fintellectual Corporate Advisors is serving as the book running lead manager for this IPO.
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.